RU2015140567A - Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами - Google Patents
Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами Download PDFInfo
- Publication number
- RU2015140567A RU2015140567A RU2015140567A RU2015140567A RU2015140567A RU 2015140567 A RU2015140567 A RU 2015140567A RU 2015140567 A RU2015140567 A RU 2015140567A RU 2015140567 A RU2015140567 A RU 2015140567A RU 2015140567 A RU2015140567 A RU 2015140567A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- pharmaceutical composition
- donepezil
- timed
- timed release
- Prior art date
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title claims 62
- 239000008194 pharmaceutical composition Substances 0.000 title claims 42
- 229960003530 donepezil Drugs 0.000 title claims 31
- 238000000338 in vitro Methods 0.000 title claims 2
- 239000000203 mixture Substances 0.000 claims 47
- 208000024827 Alzheimer disease Diseases 0.000 claims 7
- 208000028698 Cognitive impairment Diseases 0.000 claims 7
- 206010012289 Dementia Diseases 0.000 claims 7
- 208000010877 cognitive disease Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 206010029412 Nightmare Diseases 0.000 claims 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 5
- 206010022437 insomnia Diseases 0.000 claims 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN991KO2012 | 2013-02-28 | ||
| IN991/KOL/2012 | 2013-02-28 | ||
| PCT/IB2014/059302 WO2014132218A1 (en) | 2013-02-28 | 2014-02-27 | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015140567A true RU2015140567A (ru) | 2017-03-31 |
Family
ID=50288205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015140567A RU2015140567A (ru) | 2013-02-28 | 2014-02-27 | Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160015698A1 (enExample) |
| EP (1) | EP2961393B1 (enExample) |
| JP (1) | JP6429808B2 (enExample) |
| KR (1) | KR102241113B1 (enExample) |
| CN (1) | CN105163723A (enExample) |
| BR (1) | BR112015020771A2 (enExample) |
| ES (1) | ES2842208T3 (enExample) |
| MX (1) | MX378413B (enExample) |
| RU (1) | RU2015140567A (enExample) |
| WO (1) | WO2014132218A1 (enExample) |
| ZA (1) | ZA201506665B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5558648B2 (ja) * | 1998-11-23 | 2014-07-23 | デイビス、ボニー | アセチルコリンエステラーゼ阻害剤のための投与製剤 |
| US20030190360A1 (en) * | 2001-03-13 | 2003-10-09 | Baichwal Anand R. | Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment |
| MY136318A (en) * | 2002-07-25 | 2008-09-30 | Pharmacia Corp | Sustained-release tablet composition |
| CA2552221A1 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| EP1830886B1 (en) * | 2004-12-27 | 2016-04-13 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| US20060280789A1 (en) | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| US20060159753A1 (en) | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| CN101090737B (zh) * | 2004-12-27 | 2010-09-08 | 卫材R&D管理有限公司 | 稳定抗痴呆药物的方法 |
| EA014249B1 (ru) * | 2005-01-27 | 2010-10-29 | Алембик Лимитед | Формуляция леветирацетама длительного высвобождения |
| EP1874282B1 (en) * | 2005-04-06 | 2010-09-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of cns disorders |
| WO2011069076A2 (en) | 2009-12-04 | 2011-06-09 | Dr. Reddy's Laboratories Ltd. | Sustained release donepezil formulations |
| US20110218216A1 (en) | 2010-01-29 | 2011-09-08 | Kumaravel Vivek | Extended release pharmaceutical composition of donepezil |
| EP2366378A1 (en) * | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
| GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| CN102309465B (zh) * | 2010-06-30 | 2015-04-22 | 天津药物研究院 | 含盐酸多奈哌齐活性成分的缓释片及其制备方法和用途 |
| WO2012035409A1 (en) * | 2010-09-14 | 2012-03-22 | Rubicon Research Private Limited | Sustained release compositions of anti-alzheimer's agents |
-
2014
- 2014-02-27 KR KR1020157026728A patent/KR102241113B1/ko not_active Expired - Fee Related
- 2014-02-27 MX MX2015011099A patent/MX378413B/es unknown
- 2014-02-27 CN CN201480024046.5A patent/CN105163723A/zh active Pending
- 2014-02-27 JP JP2015559595A patent/JP6429808B2/ja not_active Expired - Fee Related
- 2014-02-27 RU RU2015140567A patent/RU2015140567A/ru not_active Application Discontinuation
- 2014-02-27 WO PCT/IB2014/059302 patent/WO2014132218A1/en not_active Ceased
- 2014-02-27 ES ES14710647T patent/ES2842208T3/es active Active
- 2014-02-27 EP EP14710647.0A patent/EP2961393B1/en not_active Not-in-force
- 2014-02-27 BR BR112015020771A patent/BR112015020771A2/pt not_active Application Discontinuation
- 2014-02-27 US US14/771,241 patent/US20160015698A1/en not_active Abandoned
-
2015
- 2015-09-09 ZA ZA2015/06665A patent/ZA201506665B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016513133A (ja) | 2016-05-12 |
| US20160015698A1 (en) | 2016-01-21 |
| EP2961393A1 (en) | 2016-01-06 |
| CN105163723A (zh) | 2015-12-16 |
| MX2015011099A (es) | 2016-04-06 |
| KR102241113B1 (ko) | 2021-04-15 |
| WO2014132218A1 (en) | 2014-09-04 |
| ZA201506665B (en) | 2017-02-22 |
| KR20150123302A (ko) | 2015-11-03 |
| BR112015020771A2 (pt) | 2017-07-18 |
| JP6429808B2 (ja) | 2018-11-28 |
| EP2961393B1 (en) | 2020-10-28 |
| MX378413B (es) | 2025-03-10 |
| ES2842208T3 (es) | 2021-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019048843A5 (enExample) | ||
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| JP2018514534A5 (enExample) | ||
| JP2015503593A5 (enExample) | ||
| WO2011160136A3 (en) | Progesterone containing oral dosage forms and related methods | |
| JP2015522630A5 (enExample) | ||
| RU2017112308A (ru) | Композиции и способы для лечения бессонницы | |
| JP2024069257A (ja) | Ｌ－４－クロロキヌレニンの剤形及び治療的使用 | |
| JP2017510607A5 (enExample) | ||
| RU2017127509A (ru) | Композиции и способы для улучшенного мышечного метаболизма | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| JP2016505050A5 (enExample) | ||
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| BRPI0717052A2 (pt) | Tratamento de doença reumatoide com glucocorticoide de liberação retardada | |
| JP2019507786A5 (enExample) | ||
| RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина | |
| RU2014113941A (ru) | Суспензия для перорального введения | |
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| RU2015140567A (ru) | Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами | |
| JP2019535830A5 (enExample) | ||
| JP2016514706A5 (enExample) | ||
| RU2358723C1 (ru) | Средство, обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения | |
| RU2396076C1 (ru) | Средство, уменьшающее степень острой алкогольной интоксикации (опьянения) и обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения | |
| RU2015140501A (ru) | Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами | |
| JP2017515858A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180522 |